Company Filing History:
Years Active: 1996-1998
Title: Kwon Haeng Lee: Innovating Antitumor Solutions from Seoul
Introduction
Kwon Haeng Lee is an accomplished inventor based in Seoul, South Korea, known for his innovative work in biotechnology. He has contributed significantly to the development of antitumor substances through his research and patents. With a total of two patents to his name, Kwon is making strides in the field of medical science.
Latest Patents
His latest patent, titled "Ganoderma lucidum KCCM 10045," focuses on a strain of Ganoderma lucidum IY 009 that produces a proteoglycan known as G009. This invention details the characteristics of G009, which possesses antitumoral and immunostimulating effects. The components of this proteoglycan include saccharides such as beta-glucose, alpha-glucose, galactose, alpha-mannose, and fructose, along with protein components including glycine, alanine, histidine, arginine, valine, aspartic acid, threonine, isoleucine, serine, leucine, glutamic acid, tyrosine, proline, phenylalanine, and methionine. This innovative strain has been deposited under the accession number KCCM 10045.
Career Highlights
Kwon Haeng Lee currently works at Il Yang Pharmaceutical Company, Ltd., where he continues to advance his research in pharmaceuticals. His background in biotechnology and dedication to creating effective treatments exemplify his commitment to the betterment of healthcare and the fight against cancer.
Collaborations
Throughout his career, Kwon has collaborated with fellow researchers, including Hoon Chung and Choon W Lee. Their collective efforts in research and development contribute to Kwon's ongoing success and the impact of his work in the pharmaceutical industry.
Conclusion
In summary, Kwon Haeng Lee stands as a pioneering inventor in the realm of biotechnology with his significant contributions to the development of antitumor solutions. His innovative patent on Ganoderma lucidum KCCM 10045 reflects his commitment to advancing medical science and improving patient outcomes. As he continues his work at Il Yang Pharmaceutical Company, Ltd., the potential for his inventions to make a mark in the industry remains promising.